Understanding the Differences Between MHRA and EMA GMP Expectations
Following Brexit, the regulatory landscape for pharmaceutical manufacturing in the United Kingdom has diverged from the European Union’s framework. While both the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) adhere to high standards of Good Manufacturing Practice (GMP), there are now distinct operational, procedural, and documentation expectations. This article provides a detailed comparison of MHRA and EMA GMP expectations to help manufacturers navigate dual compliance in both jurisdictions.
Regulatory Context: Post-Brexit Overview
- EMA: Continues to coordinate inspections for all EU Member States, EEA, and some third countries
- MHRA: Became an independent regulator as of 1 January 2021, retaining PIC/S alignment
- Mutual Recognition Agreements (MRAs) no longer cover routine GMP inspections between UK and EU
- Manufacturers must consider both EMA and MHRA requirements for dual market access
Inspection Planning and Risk-Based Frequency
- EMA:
- Inspections coordinated by national competent authorities (e.g., ANSM, BfArM)
- Risk-based system with centralized input via EMA’s IRIS platform
- Emphasis on GMP/GDP compliance linked to MA (Marketing Authorization) procedures
- MHRA:
- Independent inspection model under UK GMP framework
- Dynamic risk-based planning includes inspection cycles from 6 months to 3 years
- Relies on self-inspection outcomes, audit trails, and GMDP database risk scores
Documentation and
- Both EMA and MHRA expect:
- SOPs with version control, training logs, and approval signatures
- CAPA management with root cause analysis and effectiveness checks
- Traceable stability study documentation and batch release records
- MHRA-specific notes:
- Site Master File should comply with UK GMP annexes
- Annex 16 (QP certification) no longer mandates EU-qualified person but UK QP compliance is enforced
- EMA-specific notes:
- Annex 1 (sterile medicinal product guidance) is now revised and stricter in EU than UK version
- EMA GMP documentation integrates with centralized submissions (e.g., EudraGMDP)
Inspection Terminology and Deficiency Classification
- MHRA:
- Deficiencies are classified as Critical, Major, or Other
- Emphasis on real-time data access, data integrity, and procedural adherence
- EMA:
- Same deficiency classification but typically harmonized across EU Member States
- EMA GMP non-compliance statements may impact all EU-wide licenses
Qualified Person (QP) Role Comparison
- MHRA:
- UK QPs must be registered with MHRA and named on the manufacturing license
- Separate QP release required for UK domestic market unless mutual agreement exists with EU importer
- EMA:
- EU QP certification required for all products released into the EU/EEA market
- Batch release and GMP compliance tied to EMA-authorized sites
Importation and Licensing Implications
- MHRA:
- Importers must hold a UK Manufacturer’s (Import) License (MIA)
- Importer QPs must perform certification for all batches entering Great Britain
- EMA:
- Products imported from non-EU countries must be re-tested and certified by an EU QP
- Mutual recognition does not apply to routine GMP inspections from UK post-Brexit
Data Integrity and Electronic Systems
- Both agencies require:
- ALCOA+ compliance for electronic records
- Secure audit trails, access control, and system validation
- MHRA: Published standalone GxP Data Integrity guidance (2018)
- EMA: Data integrity managed through Annex 11 and reflection papers
Regulatory Communication and Enforcement
- MHRA:
- UK GMDP database publicly lists GMP certificates, non-compliance reports, and inspection dates
- Companies must notify MHRA of major changes affecting GMP or QP function
- EMA:
- Centralized reporting through EudraGMDP and the EMA IRIS platform
- Linked to pharmacovigilance and regulatory submission systems
Best Practices for Navigating Dual Regulatory Landscapes
- Develop separate compliance plans for UK and EU markets post-Brexit
- Maintain parallel QP certification records and audit-ready documentation
- Align internal SOPs to accommodate both Annex 1 (EU) and UK GMP addendums
- Participate in MHRA and EMA webinars and consultation drafts to track updates
- Use a centralized regulatory matrix to map variances in licensing, documentation, and audit response times
Conclusion
Though MHRA and EMA share foundational GMP principles, their post-Brexit operational paths have diverged, creating new compliance expectations for manufacturers. Understanding and adapting to these differences—especially in inspection planning, documentation, QP roles, and importation requirements—is essential for maintaining uninterrupted market access in both the UK and EU. With strategic preparation and regulatory awareness, pharma companies can thrive in this dual landscape.